UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials

Cancer medicine (Malden, MA), 2016-07, Vol.5 (7), p.1481-1491

2016

Link zum Volltext

Verfügbarkeit prüfen

Parental health in fellowship trainees: Fellows’ satisfaction with current policies and interest in innovation

Women's health (London, England), 2020, Vol.16, p.1745506520949417-1745506520949417

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

Investigational new drugs, 2013-10, Vol.31 (5), p.1251-1256

2013

Link zum Volltext

Verfügbarkeit prüfen

Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations

Annals of surgical oncology, 2017-10, Vol.24 (11), p.3107-3109

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

Investigational new drugs, 2024-02, Vol.42 (1), p.127-135

2024

Link zum Volltext

Verfügbarkeit prüfen

EP114/#688 Evaluating CDK 4/6 inhibitors in combination with endocrine therapy in endometrial cancers: a retrospective study

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A123-A123

2023

Link zum Volltext

Verfügbarkeit prüfen

755 Evaluating the combination of CDK 4/6 inhibitors and endocrine therapy in endometrial and ovarian cancers: a retrospective study

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A181-A181

2023

Link zum Volltext

Verfügbarkeit prüfen

896 Assessment of cystatin C and creatinine for evaluating renal function in patients receiving PARP inhibitor therapy in ovarian cancer

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A320-A320

2023

Link zum Volltext

Verfügbarkeit prüfen

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

The New England journal of medicine, 2016-12, Vol.375 (22), p.2154-2164

2016

Link zum Volltext

Verfügbarkeit prüfen

Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment

CA: a cancer journal for clinicians, 2011-09, Vol.61 (5), p.287-314

2011

Link zum Volltext

Verfügbarkeit prüfen

A multicenter analysis of treatment and outcomes in neuroendocrine carcinoma of the uterine cervix (NCUC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17518-e17518

2021

Link zum Volltext

Verfügbarkeit prüfen

NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

Cancer, 2024-04, Vol.130 (8), p.1234-1245

2024

Link zum Volltext

Verfügbarkeit prüfen

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3082-3082

2023

Link zum Volltext

Verfügbarkeit prüfen

PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A66-A66

2023

Link zum Volltext

Verfügbarkeit prüfen

Symptom identification and management in epithelial ovarian cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5554-5554

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.507-507

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5512-5512

2023

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5579-5579

2022

Link zum Volltext

Verfügbarkeit prüfen

O014/#415 Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG oncology study

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A9-A9

2022

Link zum Volltext

Verfügbarkeit prüfen

Loratadine for Paclitaxel-Induced Myalgias and Arthralgias

American journal of hospice & palliative medicine, 2020-03, Vol.37 (3), p.235-238

2020

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.5510-5510

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(35)

Publikationsform

Sprache

Englisch
(43)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Female
(10)
Ovarian Cancer
(8)
Oncology
(7)
Aged
(6)
Cancer
(6)
Middle Aged
(6)
Toxicity
(6)
Tumors
(6)
Ovarian Neoplasms - Drug Therapy
(5)
Adult
(4)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(4)
Mutation
(4)
Aged, 80 And Over
(3)
Antineoplastic Agents - Adverse Effects
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Cancer Therapies
(3)
Clinical Trials
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials

Parental health in fellowship trainees: Fellows’ satisfaction with current policies and interest in innovation

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

EP114/#688 Evaluating CDK 4/6 inhibitors in combination with endocrine therapy in endometrial cancers: a retrospective study

755 Evaluating the combination of CDK 4/6 inhibitors and endocrine therapy in endometrial and ovarian cancers: a retrospective study

896 Assessment of cystatin C and creatinine for evaluating renal function in patients receiving PARP inhibitor therapy in ovarian cancer

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment

A multicenter analysis of treatment and outcomes in neuroendocrine carcinoma of the uterine cervix (NCUC)

NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

Symptom identification and management in epithelial ovarian cancer

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses

Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer

Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study

O014/#415 Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: an NRG oncology study

Loratadine for Paclitaxel-Induced Myalgias and Arthralgias

Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers

Aktive Filter

Suchergebnisse filtern